Maze Therapeutics CSBO Sells $220,018 of Stock After Exercising Options; Company Posts Promising Phase 2 Data
Atul Dandekar, Maze Therapeutics' Chief Strategy and Business Officer, sold 7,500 shares of the company on March 30, 2026, for $220,018 and exercised options to buy 7,500 shares at $10.42 the same day. The transactions leave him with 10,503 shares and were carried out under a Rule 10b5-1 plan established in September 2025. Maze recently disclosed P…